Matuzumab in doubt after trial failure
There's trouble at Merck Serono's program for Matuzumab, which is in development for colorectal cancer. Merck KGaA says it is "reconsidering" further development of the therapy after the drug failed to hit its endpoint in a Phase II trial. Merck Serono and Takeda have a joint development pact for the drug, which failed to meet their expectations. More work, though, is being planned for other tumor types.
- check out the release
Related Articles:
Takeda expands R&D budget, may look for buyout. Report
Merck KGaA buying control of Serono. Report
Be the first to comment Rate it:
More stories about Phase II colorectal cancer development pact Takeda Merck KgAA Merck Serono Matuzumab
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight